Golden
Lung Therapeutics

Lung Therapeutics

Therapeutics for lung injury and disease company

Lung Therapeutics is a privately held, clinical stage pharmaceutical company based in Austin, Texas. It's pursues orphan drug indications for lung injury and disease due to fibrosis for which there are no effective non-surgical options. The company has two lead product candidates in its pipeline, LTI-01 and LTI-03. They focus on loculated plural effusion and idiopathic pulmonary fibrosis, respectively.

LTI-01 is an injectable, fibrinolytic drug that maximizes scar removal around the lung and thereby promotes fluid drainage while minimizing bleeding risk and other complications. Its active pharmaceutical ingredient is a proenzyme, or zymogen, which slowly becomes activated in the pleural space surrounding the lungs. LTI-01 has received orphan drug designation from both the FDA (2014) and the European Commission (2015) for the treatment of empyema. Phase 1B clinical trials are being conducted at three sites in Australia and New Zealand.

LTI-03 is a drug product that addresses Idiopathic Pulmonary Fibrosis. It is in preclinical development and has shown to resolve bleomycin-induced lung injury. It also has the potential to restore healthy lung function in patients suffering from the disease. In addition, LTI-03 has shown promise in other models of fibrotic diseases.

Timeline

People

Name
Role
Related Golden topics

Andrew Mazar

Founder & Head of Product Development

Brian Windsor

CEO

John J. Koleng

VP CMC - Inhalation Products

Stevel Idell

Founder & Chief Scientific Officer

Further reading

Title
Author
Link
Type

Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand

Lung Therapeutics, Inc.

Web

Pharma Start-up Lung Therapeutics, Inc. Achieves Significant Funding to Address Unmet Needs in Lung Injury and Disease

Lung Therapeutics, Inc.

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References